We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Optimal Nucleic Acid Yields From Archived Tissue

By Biotechdaily staff writers
Posted on 15 Mar 2006
Standard preservation techniques maintain tissue structure but complicate molecular analyses. More...
A kit has been designed to extract total nucleic acids from formaldehyde or paraformaldehyde-fixed, paraffin-embedded (FFPE) tissue.

Retrospective studies of diseased tissue at both the genomic and gene expression level depend on the ability to isolate nucleic acids from archived tissue. Preservation methods employing formaldehyde will keep the tissue structure in good condition and prevent putrefaction, but make it difficult to perform molecular analyses on samples. Nucleic acids are trapped, modified, and can also be fragmented to a degree that is incompatible with many molecular analysis techniques.

A relatively short and simple procedure has been developed to isolate nucleic acids from FFPE tissue. The RecoverAll total nucleic acid isolation kit, a product of Ambion Diagnostics (Woodward, TX, USA), yields nucleic acids that are suitable for quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR), quantitative polymerase chain reaction (qPCR), mutation screening, and microarray analyses. Samples are deparaffinized using a series of xylene and ethanol washes. Next they are subjected to a rigorous protease digestion with an incubation time tailored for the recovery of either RNA or DNA. The nucleic acids are purified using a glass-filter methodology that includes an on-filter nuclease treatment, and are eluted into either water or the low-salt buffer provided. Typical yields of more than 50% that of unfixed tissue from the same sample source can be obtained with the isolation kit.

However, further modification for downstream operations such as microarray analyses, which require purer RNA than that required for qRT-PCR, might be necessary. A longer, 2-day protease digestion time is required to release substantial amounts of DNA, which can then be used for PCR and other downstream applications.


Related Links:
Ambion Diagnostics (Asuragendx)

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Aspiration System
VACUSAFE
New
Manual Pipetting Aid
Pipette Controllers macro
New
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.